Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 95 entries
Sorted by: Best Match Show Resources per page
Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer.

Glycoconjugate journal

Yang J, Liu X, Shu J, Hou Y, Chen M, Yu H, Ma T, Du H, Zhang J, Qiao Y, He J, Niu L, Yang F, Li Z.
PMID: 32103424
Glycoconj J. 2020 Jun;37(3):373-394. doi: 10.1007/s10719-020-09910-6. Epub 2020 Feb 27.

Currently, the definitive diagnosis in breast cancer requires biopsy and histopathology, such the most effective markers are tissue-based. However, the advantages of saliva in collection and storage make it possible for assessing human pathology and contributing to the development...

Cite
Yang J, Liu X, Shu J, et al. Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer. Glycoconj J. 2020;37(3):373-394doi: 10.1007/s10719-020-09910-6.
Yang, J., Liu, X., Shu, J., Hou, Y., Chen, M., Yu, H., Ma, T., Du, H., Zhang, J., Qiao, Y., He, J., Niu, L., Yang, F., & Li, Z. (2020). Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer. Glycoconjugate journal, 37(3), 373-394. https://doi.org/10.1007/s10719-020-09910-6
Yang, Jiajun, et al. "Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer." Glycoconjugate journal vol. 37,3 (2020): 373-394. doi: https://doi.org/10.1007/s10719-020-09910-6
Yang J, Liu X, Shu J, Hou Y, Chen M, Yu H, Ma T, Du H, Zhang J, Qiao Y, He J, Niu L, Yang F, Li Z. Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer. Glycoconj J. 2020 Jun;37(3):373-394. doi: 10.1007/s10719-020-09910-6. Epub 2020 Feb 27. PMID: 32103424.
Copy Download .nbib Format: NLM
Immunomodulatory effects of four polysaccharides purified from Erythronium sibiricum bulb on macrophages.

Glycoconjugate journal

Chen C, Xie X, Li X.
PMID: 34117963
Glycoconj J. 2021 Aug;38(4):517-525. doi: 10.1007/s10719-021-10005-z. Epub 2021 Jun 12.

Four neutral polysaccharides (ESBP1-1, ESBP1-2, ESBP2-1 and ESBP3-1) were successfully purified from the water extracted crude polysaccharides of Erythronium sibiricum bulbs through the combination of DEAE Sepharose CL-6B and Sephadex G-100 chromatography; their average molecular weights were 1.3 ×...

Cite
Chen C, Xie X, Li X. Immunomodulatory effects of four polysaccharides purified from Erythronium sibiricum bulb on macrophages. Glycoconj J. 2021;38(4):517-525doi: 10.1007/s10719-021-10005-z.
Chen, C., Xie, X., & Li, X. (2021). Immunomodulatory effects of four polysaccharides purified from Erythronium sibiricum bulb on macrophages. Glycoconjugate journal, 38(4), 517-525. https://doi.org/10.1007/s10719-021-10005-z
Chen, Chunli, et al. "Immunomodulatory effects of four polysaccharides purified from Erythronium sibiricum bulb on macrophages." Glycoconjugate journal vol. 38,4 (2021): 517-525. doi: https://doi.org/10.1007/s10719-021-10005-z
Chen C, Xie X, Li X. Immunomodulatory effects of four polysaccharides purified from Erythronium sibiricum bulb on macrophages. Glycoconj J. 2021 Aug;38(4):517-525. doi: 10.1007/s10719-021-10005-z. Epub 2021 Jun 12. PMID: 34117963.
Copy Download .nbib Format: NLM
Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods.

Glycoconjugate journal

Demus D, Jansen BC, Gardner RA, Urbanowicz PA, Wu H, Štambuk T, Juszczak A, Medvidović EP, Juge N, Gornik O, Owen KR, Spencer DIR.
PMID: 33765222
Glycoconj J. 2021 Jun;38(3):375-386. doi: 10.1007/s10719-021-09992-w. Epub 2021 Mar 25.

Antennary fucosylation alterations in plasma glycoproteins have been previously proposed and tested as a biomarker for differentiation of maturity onset diabetes of the young (MODY) patients carrying a functional mutation in the HNF1A gene. Here, we developed a novel...

Cite
Demus D, Jansen BC, Gardner RA, et al. Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods. Glycoconj J. 2021;38(3):375-386doi: 10.1007/s10719-021-09992-w.
Demus, D., Jansen, B. C., Gardner, R. A., Urbanowicz, P. A., Wu, H., Štambuk, T., Juszczak, A., Medvidović, E. P., Juge, N., Gornik, O., Owen, K. R., & Spencer, D. I. R. (2021). Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods. Glycoconjugate journal, 38(3), 375-386. https://doi.org/10.1007/s10719-021-09992-w
Demus, Daniel, et al. "Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods." Glycoconjugate journal vol. 38,3 (2021): 375-386. doi: https://doi.org/10.1007/s10719-021-09992-w
Demus D, Jansen BC, Gardner RA, Urbanowicz PA, Wu H, Štambuk T, Juszczak A, Medvidović EP, Juge N, Gornik O, Owen KR, Spencer DIR. Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods. Glycoconj J. 2021 Jun;38(3):375-386. doi: 10.1007/s10719-021-09992-w. Epub 2021 Mar 25. PMID: 33765222; PMCID: PMC8116301.
Copy Download .nbib Format: NLM
Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Glycoconjugate journal

Yahi N, Di Scala C, Chahinian H, Fantini J.
PMID: 34328594
Glycoconj J. 2021 Jul 30; doi: 10.1007/s10719-021-10012-0. Epub 2021 Jul 30.

Parkinson's disease (PD) is a major neurodegenerative disorder which exhibits many of the characteristics of a pandemic. Current therapeutic strategies are centered on the dopaminergic system, with limited efficacy, so that a treatment that has a direct impact on...

Cite
Yahi N, Di Scala C, Chahinian H, et al. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease. Glycoconj J. 2021;doi: 10.1007/s10719-021-10012-0.
Yahi, N., Di Scala, C., Chahinian, H., & Fantini, J. (2021). Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease. Glycoconjugate journal, . https://doi.org/10.1007/s10719-021-10012-0
Yahi, Nouara, et al. "Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease." Glycoconjugate journal vol. (2021). doi: https://doi.org/10.1007/s10719-021-10012-0
Yahi N, Di Scala C, Chahinian H, Fantini J. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease. Glycoconj J. 2021 Jul 30; doi: 10.1007/s10719-021-10012-0. Epub 2021 Jul 30. PMID: 34328594.
Copy Download .nbib Format: NLM
Carbohydrate based meningococcal vaccines: past and present overview.

Glycoconjugate journal

Berti F, Romano MR, Micoli F, Adamo R.
PMID: 33905086
Glycoconj J. 2021 Aug;38(4):401-409. doi: 10.1007/s10719-021-09990-y. Epub 2021 Apr 27.

Neisseria meningitidis is a major cause of bacterial meningitidis worldwide. Children less than five years and adolescents are particularly affected. Nearly all invasive strains are surrounded by a polysaccharide capsule, based on which, 12 N. meningitidis serogroups are differentiated....

Cite
Berti F, Romano MR, Micoli F, et al. Carbohydrate based meningococcal vaccines: past and present overview. Glycoconj J. 2021;38(4):401-409doi: 10.1007/s10719-021-09990-y.
Berti, F., Romano, M. R., Micoli, F., & Adamo, R. (2021). Carbohydrate based meningococcal vaccines: past and present overview. Glycoconjugate journal, 38(4), 401-409. https://doi.org/10.1007/s10719-021-09990-y
Berti, Francesco, et al. "Carbohydrate based meningococcal vaccines: past and present overview." Glycoconjugate journal vol. 38,4 (2021): 401-409. doi: https://doi.org/10.1007/s10719-021-09990-y
Berti F, Romano MR, Micoli F, Adamo R. Carbohydrate based meningococcal vaccines: past and present overview. Glycoconj J. 2021 Aug;38(4):401-409. doi: 10.1007/s10719-021-09990-y. Epub 2021 Apr 27. PMID: 33905086; PMCID: PMC8076658.
Copy Download .nbib Format: NLM
Metal cations promote α-dicarbonyl formation in glucose-containing peritoneal dialysis fluids.

Glycoconjugate journal

Gensberger-Reigl S, Auditore A, Huppert J, Pischetsrieder M.
PMID: 33283256
Glycoconj J. 2021 Jun;38(3):319-329. doi: 10.1007/s10719-020-09964-6. Epub 2020 Dec 07.

Heat sterilization of peritoneal dialysis fluids (PDFs) leads to the formation of glucose degradation products (GDPs), which impair long-term peritoneal dialysis. The current study investigated the effects of metal ions, which occur as trace impurities in the fluids, on...

Cite
Gensberger-Reigl S, Auditore A, Huppert J, et al. Metal cations promote α-dicarbonyl formation in glucose-containing peritoneal dialysis fluids. Glycoconj J. 2020;38(3):319-329doi: 10.1007/s10719-020-09964-6.
Gensberger-Reigl, S., Auditore, A., Huppert, J., & Pischetsrieder, M. (2021). Metal cations promote α-dicarbonyl formation in glucose-containing peritoneal dialysis fluids. Glycoconjugate journal, 38(3), 319-329. https://doi.org/10.1007/s10719-020-09964-6
Gensberger-Reigl, Sabrina, et al. "Metal cations promote α-dicarbonyl formation in glucose-containing peritoneal dialysis fluids." Glycoconjugate journal vol. 38,3 (2021): 319-329. doi: https://doi.org/10.1007/s10719-020-09964-6
Gensberger-Reigl S, Auditore A, Huppert J, Pischetsrieder M. Metal cations promote α-dicarbonyl formation in glucose-containing peritoneal dialysis fluids. Glycoconj J. 2021 Jun;38(3):319-329. doi: 10.1007/s10719-020-09964-6. Epub 2020 Dec 07. PMID: 33283256; PMCID: PMC8116238.
Copy Download .nbib Format: NLM
Metabolic transit of dietary advanced glycation end-products - the case of N.

Glycoconjugate journal

Tessier FJ, Boulanger E, Howsam M.
PMID: 32990827
Glycoconj J. 2021 Jun;38(3):311-317. doi: 10.1007/s10719-020-09950-y. Epub 2020 Sep 29.

The Maillard reaction, also called glycation, is one of the major chemical reactions responsible for most yellow-to-brown colors and aromas in cooked foods. This reaction between reducing sugars and amino functions on proteins affects not only the flavor of...

Cite
Tessier FJ, Boulanger E, Howsam M. Metabolic transit of dietary advanced glycation end-products - the case of N. Glycoconj J. 2020;38(3):311-317doi: 10.1007/s10719-020-09950-y.
Tessier, F. J., Boulanger, E., & Howsam, M. (2021). Metabolic transit of dietary advanced glycation end-products - the case of N. Glycoconjugate journal, 38(3), 311-317. https://doi.org/10.1007/s10719-020-09950-y
Tessier, Frederic J, et al. "Metabolic transit of dietary advanced glycation end-products - the case of N." Glycoconjugate journal vol. 38,3 (2021): 311-317. doi: https://doi.org/10.1007/s10719-020-09950-y
Tessier FJ, Boulanger E, Howsam M. Metabolic transit of dietary advanced glycation end-products - the case of N. Glycoconj J. 2021 Jun;38(3):311-317. doi: 10.1007/s10719-020-09950-y. Epub 2020 Sep 29. PMID: 32990827.
Copy Download .nbib Format: NLM
The oligosaccharide portion of ganglioside GM1 regulates mitochondrial function in neuroblastoma cells.

Glycoconjugate journal

Fazzari M, Audano M, Lunghi G, Di Biase E, Loberto N, Mauri L, Mitro N, Sonnino S, Chiricozzi E.
PMID: 32266604
Glycoconj J. 2020 Jun;37(3):293-306. doi: 10.1007/s10719-020-09920-4. Epub 2020 Apr 08.

The crucial role of ganglioside GM1 in the regulation of neural homeostasis has been assessed by several studies. Recently we shed new light on the molecular basis underlying GM1 effects demonstrating that GM1 oligosaccharide directly binds TrkA receptor and...

Cite
Fazzari M, Audano M, Lunghi G, et al. The oligosaccharide portion of ganglioside GM1 regulates mitochondrial function in neuroblastoma cells. Glycoconj J. 2020;37(3):293-306doi: 10.1007/s10719-020-09920-4.
Fazzari, M., Audano, M., Lunghi, G., Di Biase, E., Loberto, N., Mauri, L., Mitro, N., Sonnino, S., & Chiricozzi, E. (2020). The oligosaccharide portion of ganglioside GM1 regulates mitochondrial function in neuroblastoma cells. Glycoconjugate journal, 37(3), 293-306. https://doi.org/10.1007/s10719-020-09920-4
Fazzari, Maria, et al. "The oligosaccharide portion of ganglioside GM1 regulates mitochondrial function in neuroblastoma cells." Glycoconjugate journal vol. 37,3 (2020): 293-306. doi: https://doi.org/10.1007/s10719-020-09920-4
Fazzari M, Audano M, Lunghi G, Di Biase E, Loberto N, Mauri L, Mitro N, Sonnino S, Chiricozzi E. The oligosaccharide portion of ganglioside GM1 regulates mitochondrial function in neuroblastoma cells. Glycoconj J. 2020 Jun;37(3):293-306. doi: 10.1007/s10719-020-09920-4. Epub 2020 Apr 08. PMID: 32266604.
Copy Download .nbib Format: NLM
Browning and pigmentation in food through the Maillard reaction.

Glycoconjugate journal

Murata M.
PMID: 32910400
Glycoconj J. 2021 Jun;38(3):283-292. doi: 10.1007/s10719-020-09943-x. Epub 2020 Sep 10.

The Maillard reaction was discovered in 1912 by Louis C. Maillard when he observed the browning phenomena with aroma formation in a heated solution containing a sugar and an amino acid. The Maillard reaction starts from the reactions between...

Cite
Murata M. Browning and pigmentation in food through the Maillard reaction. Glycoconj J. 2020;38(3):283-292doi: 10.1007/s10719-020-09943-x.
Murata, M. (2021). Browning and pigmentation in food through the Maillard reaction. Glycoconjugate journal, 38(3), 283-292. https://doi.org/10.1007/s10719-020-09943-x
Murata, Masatsune. "Browning and pigmentation in food through the Maillard reaction." Glycoconjugate journal vol. 38,3 (2021): 283-292. doi: https://doi.org/10.1007/s10719-020-09943-x
Murata M. Browning and pigmentation in food through the Maillard reaction. Glycoconj J. 2021 Jun;38(3):283-292. doi: 10.1007/s10719-020-09943-x. Epub 2020 Sep 10. PMID: 32910400.
Copy Download .nbib Format: NLM
A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.

Glycoconjugate journal

Schneider JS.
PMID: 34037912
Glycoconj J. 2021 May 26; doi: 10.1007/s10719-021-10002-2. Epub 2021 May 26.

Parkinson's disease (PD) is slowly progressing neurodegenerative disorder that affects millions of patients worldwide. While effective symptomatic therapies for PD exist, there is no currently available disease modifying agent to slow or stop the progression of the disease. Many...

Cite
Schneider JS. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. Glycoconj J. 2021;doi: 10.1007/s10719-021-10002-2.
Schneider, J. S. (2021). A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. Glycoconjugate journal, . https://doi.org/10.1007/s10719-021-10002-2
Schneider, J S. "A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease." Glycoconjugate journal vol. (2021). doi: https://doi.org/10.1007/s10719-021-10002-2
Schneider JS. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. Glycoconj J. 2021 May 26; doi: 10.1007/s10719-021-10002-2. Epub 2021 May 26. PMID: 34037912.
Copy Download .nbib Format: NLM
Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates.

Glycoconjugate journal

Campisi E, Rosini R, Romano MR, Balducci E, Pinto V, Brogioni B, De Ricco R, Fabbrini M, Spagnuolo A, Chiarot E, Berti F, Margarit I.
PMID: 33956253
Glycoconj J. 2021 Aug;38(4):447-457. doi: 10.1007/s10719-021-10000-4. Epub 2021 May 06.

The capsular polysaccharide of the human pathogen Group B Streptococcus is a key virulence factor and vaccine candidate that induces protective antibodies when conjugated to carrier proteins. It consists of long polymeric chains of oligosaccharide repeating units, and each...

Cite
Campisi E, Rosini R, Romano MR, et al. Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates. Glycoconj J. 2021;38(4):447-457doi: 10.1007/s10719-021-10000-4.
Campisi, E., Rosini, R., Romano, M. R., Balducci, E., Pinto, V., Brogioni, B., De Ricco, R., Fabbrini, M., Spagnuolo, A., Chiarot, E., Berti, F., & Margarit, I. (2021). Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates. Glycoconjugate journal, 38(4), 447-457. https://doi.org/10.1007/s10719-021-10000-4
Campisi, Edmondo, et al. "Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates." Glycoconjugate journal vol. 38,4 (2021): 447-457. doi: https://doi.org/10.1007/s10719-021-10000-4
Campisi E, Rosini R, Romano MR, Balducci E, Pinto V, Brogioni B, De Ricco R, Fabbrini M, Spagnuolo A, Chiarot E, Berti F, Margarit I. Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates. Glycoconj J. 2021 Aug;38(4):447-457. doi: 10.1007/s10719-021-10000-4. Epub 2021 May 06. PMID: 33956253; PMCID: PMC8100357.
Copy Download .nbib Format: NLM
The development and characterization of an E. coli O25B bioconjugate vaccine.

Glycoconjugate journal

Kowarik M, Wetter M, Haeuptle MA, Braun M, Steffen M, Kemmler S, Ravenscroft N, De Benedetto G, Zuppiger M, Sirena D, Cescutti P, Wacker M.
PMID: 33730261
Glycoconj J. 2021 Aug;38(4):421-435. doi: 10.1007/s10719-021-09985-9. Epub 2021 Mar 17.

Extraintestinal pathogenic Escherichia coli (ExPEC) cause a wide range of clinical diseases such as bacteremia and urinary tract infections. The increase of multidrug resistant ExPEC strains is becoming a major concern for the treatment of these infections and E....

Cite
Kowarik M, Wetter M, Haeuptle MA, et al. The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J. 2021;38(4):421-435doi: 10.1007/s10719-021-09985-9.
Kowarik, M., Wetter, M., Haeuptle, M. A., Braun, M., Steffen, M., Kemmler, S., Ravenscroft, N., De Benedetto, G., Zuppiger, M., Sirena, D., Cescutti, P., & Wacker, M. (2021). The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconjugate journal, 38(4), 421-435. https://doi.org/10.1007/s10719-021-09985-9
Kowarik, Michael, et al. "The development and characterization of an E. coli O25B bioconjugate vaccine." Glycoconjugate journal vol. 38,4 (2021): 421-435. doi: https://doi.org/10.1007/s10719-021-09985-9
Kowarik M, Wetter M, Haeuptle MA, Braun M, Steffen M, Kemmler S, Ravenscroft N, De Benedetto G, Zuppiger M, Sirena D, Cescutti P, Wacker M. The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J. 2021 Aug;38(4):421-435. doi: 10.1007/s10719-021-09985-9. Epub 2021 Mar 17. PMID: 33730261; PMCID: PMC8260533.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 95 entries